Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2014—Randox released a white paper focusing on the importance of quality control in point-of-care testing. The white paper will help laboratories define an appropriate QC procedure for all point-of-care devices.
November 2014—The ConfirmMDx for Prostate Cancer test, from MDxHealth, qualifies for Medicare coverage effective Nov. 3, 2014. The Centers for Medicare and Medicaid Services released the final version of the coverage policy issued by Palmetto GBA: MoIDX title: ConfirmMDx Epigenetic Molecular Assay, LCD No.: L35368.
November 2014—The Henry M. Jackson Foundation for the Advancement of Military Medicine has been awarded a patent in the U.S. and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada, and Japan.
November 2014—The Food and Drug Administration is allowing the marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury in the 12 hours following administration of the test. Early knowledge that a patient is likely to develop AKI may prompt closer patient monitoring and help prevent permanent kidney damage or death, according to the agency.
November 2014—Eppendorf has launched the Mastercycler Nexus X2, a molecular biology instrument for researchers looking to carry out two PCR reactions simultaneously, without compromising the number of samples.
November 2014—BrandTech Scientific announced the availability of inertGrade microplates for the cultivation of nonadherent cell lines, spheroids, and stem cells in a 96-well plate format. The polystyrene plates are treated with a proprietary hydrogel that creates a hydrophobic interface between the surface of the plastic and cellular material to inhibit cell and protein attachment.
November 2014—Dako, an Agilent Technologies company, announced the EU launch of HER2 IQFISH pharmDx automated on Dako Omnis. The assay will enable pathology laboratories to integrate the Dako HER2 IQFISH and IQFISH hybridization buffer into their immunohistochemistry workflow.
November 2014—Sirion Biotech, in cooperation with University of Munich and University of Cologne, developed a line of viral vectors with specific promoters that are only active in a targeted set of cells to initiate the desired gene expression. Using this method, the gene of interest is being expressed only in the targeted tissue relevant to the desired therapy. The method is designed to improve the effectiveness of therapy and reduce the likelihood of side effects.
November 2014—NanoString Technologies announced a highly multiplexed gene expression panel for the nCounter Analysis System, the PanCancer Immune Profiling Panel. The panel will enable researchers to create profiles of the human immune response in all cancer types, potentially accelerating the discovery and development of drugs, therapies, and predictive biomarker signatures for immunotherapy treatment response.
November 2014—Ventana Medical Systems announced that its Ventana System for Primary Diagnosis has been CE marked in the European Union for routine pathology, including for primary diagnosis with human tissue specimens.
